“Patient identifiers” were defined as the patient’s name, date of birth, and sex.

Results Descriptive information Of the 267 fracture patients, a total of 103 had a BMD scheduled or performed at the 6-month follow-up data collection time point. Of these, 53 BMD reports (51 %) were received from the referring physician. Five reports were excluded from the present analysis PF-02341066 price because they pre-dated the participants’ fracture (n = 2), were produced by a clinic outside of Ontario (n = 1), or were incomplete with only one of two pages received (n = 2). This resulted in 48 BMD reports eligible for analysis representing 27 baseline and 21 repeat scans. The 48 BMD reports were produced by a total of 27 independent BMD scanning facilities, including 19 hospitals, between May of 2007 and October of 2008. About one half of the scans were produced by BMD facilities in small towns (<30,000 population). The

demographic characteristics of the patients represented in this sample of BMD reports are provided in Table 1. The mean age was 67.2 years (SD ± 10.9 years). Approximately three-quarters BAY 73-4506 order were women, and 43.8 % had received a prior BMD test. Table 1 Demographic characteristics: patients (n = 48) Characteristic Mean (SD) or N (%) Age in years 67.2 (10.9) Under age 50 2 (4.1 %) Female 36 (75.0 %) Prior BMD test 21 (43.8 %) Fracture risk assessment review Tables 2 and 3 summarize the results of the fracture risk assessment review. Of the 48 reports, 42 (87.5 %) contained a fracture risk assessment. Of note, on two reports that did not report fracture risk, a statement was made that fracture risk assessments were not valid for individuals receiving treatment for osteoporosis. Moreover, of those reports that contained a fracture risk assessment, ten (20.8 %) reported multiple fracture

risks (i.e., one for every imaged site). Table 2 Fracture risk assessment review Quality indicator Baseline reports (total = 27) Repeat reports (total = 21) All reports (total = 48) N (%) N (%) N (%) Reports including a risk assessment 25 (92.6) FAD 17 (81.0) 42 (87.5) Reports with multiple risk assessments 6 (22.2) 4 (19.0) 10 (20.8) Risk incorporating BMD + {Selleck Anti-diabetic Compound Library|Selleck Antidiabetic Compound Library|Selleck Anti-diabetic Compound Library|Selleck Antidiabetic Compound Library|Selleckchem Anti-diabetic Compound Library|Selleckchem Antidiabetic Compound Library|Selleckchem Anti-diabetic Compound Library|Selleckchem Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|buy Anti-diabetic Compound Library|Anti-diabetic Compound Library ic50|Anti-diabetic Compound Library price|Anti-diabetic Compound Library cost|Anti-diabetic Compound Library solubility dmso|Anti-diabetic Compound Library purchase|Anti-diabetic Compound Library manufacturer|Anti-diabetic Compound Library research buy|Anti-diabetic Compound Library order|Anti-diabetic Compound Library mouse|Anti-diabetic Compound Library chemical structure|Anti-diabetic Compound Library mw|Anti-diabetic Compound Library molecular weight|Anti-diabetic Compound Library datasheet|Anti-diabetic Compound Library supplier|Anti-diabetic Compound Library in vitro|Anti-diabetic Compound Library cell line|Anti-diabetic Compound Library concentration|Anti-diabetic Compound Library nmr|Anti-diabetic Compound Library in vivo|Anti-diabetic Compound Library clinical trial|Anti-diabetic Compound Library cell assay|Anti-diabetic Compound Library screening|Anti-diabetic Compound Library high throughput|buy Antidiabetic Compound Library|Antidiabetic Compound Library ic50|Antidiabetic Compound Library price|Antidiabetic Compound Library cost|Antidiabetic Compound Library solubility dmso|Antidiabetic Compound Library purchase|Antidiabetic Compound Library manufacturer|Antidiabetic Compound Library research buy|Antidiabetic Compound Library order|Antidiabetic Compound Library chemical structure|Antidiabetic Compound Library datasheet|Antidiabetic Compound Library supplier|Antidiabetic Compound Library in vitro|Antidiabetic Compound Library cell line|Antidiabetic Compound Library concentration|Antidiabetic Compound Library clinical trial|Antidiabetic Compound Library cell assay|Antidiabetic Compound Library screening|Antidiabetic Compound Library high throughput|Anti-diabetic Compound high throughput screening| modifying factors 7 (25.9) 5 (23.8) 12 (25.0) Risk incorporating BMD alone 15 (55.6) 12 (57.1) 27 (56.3)  “Moderate” riska reported as “low”  10 (37.0)  6 (28.6)  16 (33.3)  “High” riska reported as “moderate”  5 (18.5)  6 (28.6)  11 (22.9) Reports for patients >50 with no risk assessment 2 (7.4) 4 (19.1) 6 (12.5) Reports for patients <50 with risk assessment 1 (3.7) 0 (0.0) 1 (2.1) Reports with explicit mention of fracture 5 (18.5) 4 (19.1) 9 (18.